A large percentage of glioblastomas are resistant to temozolomide due to the coactivation of the epidermal growth factor receptor (EGFR) family and receptor tyrosine kinase proteins, including mesenchymal‐epithelial transition factor (MET). This evidence concerns the gene EGFR and glioblastoma.